NSGC 2026 has ended. This guide stays up as the record of who was there. Next: NSGC 2027, Nov 7–11, 2027 in Tampa
Pharma and biotech companies at NSGC 2026
Nov 10–14, 2026 Baltimore, MD ~2.5k attendees Website
21 pharma and biotech companies are at NSGC 2026 — 7 presentations on the program and 21 with a booth in the exhibit hall. 21 of them have their own page in this guide. As of Nov 12, 2026.
Topic
Showing 1–17 of 21 organizations
| Organization | NSGC 2026 Attendance |
|---|---|
Acadia Pharmaceuticals San Diego, CA | |
Biopharmaceutical company with approved treatments for Rett syndrome and Parkinson's disease psychosis, developing further medicines for neurological and rare conditions. | Booth Exhibiting at Booth 963 Wed, Nov 1110am–12:15pm · 3–6:30pmThu, Nov 1210:15am–12:15pm · 3–5:30pmFri, Nov 1310:15am–12:15pm Symposium Fri Nov 13 7:45–8:30am Rett Syndrome Management Your Way: Two Formulations of the First and Only FDA-Approved Treatment Covers Rett syndrome care with both forms of Acadia's FDA-approved Rett treatment, DAYBUE and DAYBUE STIX. |
Alexion, AstraZeneca Rare Disease Boston, MA | |
AstraZeneca's rare disease company, with medicines for conditions including hypophosphatasia, lysosomal acid lipase deficiency, neurofibromatosis type 1 and complement disorders. | Booth Exhibiting at Booth 1155 Wed, Nov 1110am–12:15pm · 3–6:30pmThu, Nov 1210:15am–12:15pm · 3–5:30pmFri, Nov 1310:15am–12:15pm Symposium Fri Nov 13 12:15–1:30pm Recognize What Might Be Missed: Changing the Patient Journey in HPP, LAL-D, NF1 Reviews the clinical clues to hypophosphatasia, lysosomal acid lipase deficiency and neurofibromatosis type 1, to help clinicians recognize them earlier. |
Ascendis Pharma Copenhagen, Denmark | |
Biopharmaceutical company developing long-acting treatments for rare endocrine and skeletal conditions, including achondroplasia. | Booth Exhibiting at Booth 1055 Wed, Nov 1110am–12:15pm · 3–6:30pmThu, Nov 1210:15am–12:15pm · 3–5:30pmFri, Nov 1310:15am–12:15pm Symposium Wed Nov 11 7:45–8:30am Discover Yuviwel® (navepegritide) Introduces Ascendis' Yuviwel (navepegritide), covering how it works, its clinical trial results and how it is dosed. |
BioMarin San Rafael, CA | |
Biotech company with medicines for rare genetic conditions, including achondroplasia and other skeletal disorders, PKU and several lysosomal storage disorders. | Booth Exhibiting at Booth 1150, 1243, 1342 Wed, Nov 1110am–12:15pm · 3–6:30pmThu, Nov 1210:15am–12:15pm · 3–5:30pmFri, Nov 1310:15am–12:15pm Symposium Thu Nov 12 7:45–8:30am Hypochondroplasia: Advancing Diagnosis and Genetic Counseling in an Evolving Clinical Landscape Follows patients with hypochondroplasia from first suspicion to genetic confirmation and counseling, including FGFR3 variant interpretation and emerging treatments. |
BridgeBio Palo Alto, CA | |
Biotech company developing medicines for genetic conditions, including transthyretin amyloid cardiomyopathy and achondroplasia. | Booth Exhibiting at Booth 1247, 1347 Wed, Nov 1110am–12:15pm · 3–6:30pmThu, Nov 1210:15am–12:15pm · 3–5:30pmFri, Nov 1310:15am–12:15pm Symposium Fri Nov 13 7:45–8:30am One Diagnosis, Many Conversations: The Evolving Landscape of Care in Achondroplasia and the Role of Genetic Counselors Traces achondroplasia care from prenatal recognition through childhood treatment choices to adult family planning, and the genetic counselor's role throughout. |
Lilly Indianapolis, IN | |
Global pharmaceutical company whose genetic medicine work includes gene therapy for hereditary hearing loss; sponsors a session on hearing loss genetic testing. | Booth Exhibiting at Booth 1363 Wed, Nov 1110am–12:15pm · 3–6:30pmThu, Nov 1210:15am–12:15pm · 3–5:30pmFri, Nov 1310:15am–12:15pm Symposium Fri Nov 13 7:45–8:30am Partners in Diagnosis: Collaborative Models for Genetic Testing and Counseling in Hereditary Hearing Loss Uses hereditary hearing loss to show how genetic counselors, audiologists and otolaryngologists can team up so genetic testing is routinely offered. |
Sanofi Paris, France | |
Global pharmaceutical company with rare disease medicines, including enzyme replacement therapies for Gaucher, Pompe and Fabry disease. | Booth Exhibiting at Booth 1148, 1165 Wed, Nov 1110am–12:15pm · 3–6:30pmThu, Nov 1210:15am–12:15pm · 3–5:30pmFri, Nov 1310:15am–12:15pm Symposium Fri Nov 13 12:15–1:30pm One Rare Disease, Three Perspectives: How Genetic Counselors Across Clinic, Research, and Industry Shape Patient Care Uses Gaucher disease type 3 to show how genetic counselors in clinics, research and industry each shape diagnosis and care. |
Biotech company, now a BioMarin subsidiary, with treatments for the lysosomal storage disorders Fabry disease and Pompe disease. | Booth Exhibiting at Booth 1352 Wed, Nov 1110am–12:15pm · 3–6:30pmThu, Nov 1210:15am–12:15pm · 3–5:30pmFri, Nov 1310:15am–12:15pm |
Arrowhead Pharmaceuticals Pasadena, CA | |
Biotech company developing RNA interference medicines, including treatments for severe triglyceride disorders and homozygous familial hypercholesterolemia. | Booth Exhibiting at Booth 1050 Wed, Nov 1110am–12:15pm · 3–6:30pmThu, Nov 1210:15am–12:15pm · 3–5:30pmFri, Nov 1310:15am–12:15pm |
Public benefit biotech company developing adrabetadex, an investigational treatment for Niemann-Pick disease type C. | Booth Exhibiting at Booth 1254 Wed, Nov 1110am–12:15pm · 3–6:30pmThu, Nov 1210:15am–12:15pm · 3–5:30pmFri, Nov 1310:15am–12:15pm |
Chiesi Global Rare Diseases Boston, MA | |
Rare disease unit of the Chiesi Group developing treatments for lysosomal storage disorders such as Fabry disease and alpha-mannosidosis. | Booth Exhibiting at Booth 1456 Wed, Nov 1110am–12:15pm · 3–6:30pmThu, Nov 1210:15am–12:15pm · 3–5:30pmFri, Nov 1310:15am–12:15pm |
Biotech company developing treatments for rare neurodegenerative diseases, including Niemann-Pick disease type C. | Booth Exhibiting at Booth 1246 Wed, Nov 1110am–12:15pm · 3–6:30pmThu, Nov 1210:15am–12:15pm · 3–5:30pmFri, Nov 1310:15am–12:15pm |
Ionis Pharmaceuticals Carlsbad, CA | |
Biotech company developing RNA-targeted medicines, with marketed drugs and a pipeline in neurology, cardiology and rare diseases. | Booth Exhibiting at Booth 1070 Wed, Nov 1110am–12:15pm · 3–6:30pmThu, Nov 1210:15am–12:15pm · 3–5:30pmFri, Nov 1310:15am–12:15pm |
Biotech company developing therapies for diseases caused by mitochondrial dysfunction, aiming to correct cellular energy deficits. | Booth Exhibiting at Booth 1361 Wed, Nov 1110am–12:15pm · 3–6:30pmThu, Nov 1210:15am–12:15pm · 3–5:30pmFri, Nov 1310:15am–12:15pm |
Mirum Pharmaceuticals Foster City, CA | |
Biopharmaceutical company with medicines for rare diseases, including rare cholestatic liver diseases and fibrodysplasia ossificans progressiva. | Booth Exhibiting at Booth 1276 Wed, Nov 1110am–12:15pm · 3–6:30pmThu, Nov 1210:15am–12:15pm · 3–5:30pmFri, Nov 1310:15am–12:15pm |
Pfizer New York, NY | |
Global pharmaceutical company whose oncology unit develops small molecules, antibody-drug conjugates and bispecifics for breast, genitourinary, blood and lung cancers. | Booth Exhibiting at Booth 1478 Wed, Nov 1110am–12:15pm · 3–6:30pmThu, Nov 1210:15am–12:15pm · 3–5:30pmFri, Nov 1310:15am–12:15pm |
PTC Therapeutics Warren, NJ | |
Biopharmaceutical company with medicines for rare genetic diseases, including Duchenne muscular dystrophy, AADC deficiency and phenylketonuria (PKU). | Booth Exhibiting at Booth 1253 Wed, Nov 1110am–12:15pm · 3–6:30pmThu, Nov 1210:15am–12:15pm · 3–5:30pmFri, Nov 1310:15am–12:15pm |
Find buyers from pharma and biotech companies
Tell us what you sell and we’ll find the people at these pharma and biotech companies most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Browse NSGC 2026 by
Organization type
- Testing labs 24
- Biopharma 21
- Clinics 12
- Research 4
- Advocacy 19
Topic
Exhibit hall
Everyone
Not affiliated with or endorsed by the National Society of Genetic Counselors (NSGC). Organization details are derived from NSGC’s published exhibitor list and program, and each organization’s own website. Submit a correction